Canagliflozin
- Generic Name
- Canagliflozin
- Brand Names
- Invokamet, Invokana
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25FO5S
- CAS Number
- 842133-18-0
- Unique Ingredient Identifier
- 6S49DGR869
- Background
Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise .
...
- Indication
This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus .
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Major Adverse Cardiac Events, Type 2 Diabetes Mellitus, Doubling of serum creatinine
- Associated Therapies
- -
Treatment of Diabetes in Patients With Systolic Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 36
- Registration Number
- NCT02920918
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 16
- Registration Number
- NCT02912455
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
Genetics of Response to Canagliflozin
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 700
- Registration Number
- NCT02891954
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
- Conditions
- Interventions
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT02865668
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
- Conditions
- Interventions
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT02851212
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants
- Conditions
- Interventions
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT02851095
Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan
- Conditions
- Interventions
- First Posted Date
- 2016-02-29
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- University of Leicester
- Target Recruit Count
- 25
- Registration Number
- NCT02694263
- Locations
- 🇬🇧
University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom
🇬🇧University Hospitals Birmingham NHS Foundation Trust, Birmingham, West Midlands, United Kingdom
Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion
- Conditions
- Interventions
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Yale University
- Target Recruit Count
- 10
- Registration Number
- NCT02673138
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Canagliflozin-Mealtime Insulin Rescue
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2022-08-15
- Target Recruit Count
- 40
- Registration Number
- NCT02624908
- Locations
- 🇺🇸
Atlanta VA Medical Center, Decatur, Georgia, United States
The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Joslin Diabetes Center
- Registration Number
- NCT02597309
- Locations
- 🇺🇸
Joslin Diabetes Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.